PARP inhibitors and prostate cancer: A new era of precision medicine
Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
4 Aug 2020
Oncology pharmacist perspective on PARP inhibitors for castration-resistant pros...
Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA
27 Jul 2020
The role of PARP-2 in inhibiting prostate cancer
Prof Li Jia - Harvard Medical School, Boston, USA
27 Jul 2020
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advan...
Prof Scott Tykodi - University of Washington, Seattle, USA
14 Jul 2020
Association of gene expression with clinical outcomes in RCC patients treated wi...
Prof Scott Tykodi - University of Washington, Seattle, USA
14 Jul 2020
Renal cell cancer: Highlights from ASCO 2020
Prof Scott Tykodi - University of Washington, Seattle, USA
13 Jul 2020
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-re...
Prof Scott Tykodi - University of Washington, Seattle, USA
13 Jul 2020
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer
Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA
10 Jul 2020
The future of PARP inhibitors in prostate cancer
Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain
2 Jul 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer
Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
24 Jun 2020
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2...
Prof Robert Huddart and Dr Ignacio Durán
15 Jun 2020
